Date: 2016-12-15
Type of information: Nomination
Compound: chairman of the board of directors
Company: Confo Therapeutics (Belgium)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 15, 2016, Confo Therapeutics announced the appointment of John Edward Berriman as non-executive director and chairman of the board of directors, starting December 21.
- John Berriman is currently Chairman of ReNeuron Group , Autifony Therapeutics and Depixus ; and a non-executive director of Autolus. He has served as Chairman of Heptares Therapeutics (sold to Sosei in February 2015) and Algeta (sold to Bayer in 2014) and was a director of Micromet until its sale to Amgen in 2012. Previously he was a director of Abingworth Management where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA, many of which obtained listings on public stock exchanges. Prior to that, John spent 14 years with Celltech and was a member of its Board when it listed on the London Stock Exchange in 1994. He has a degree in Chemical Engineering from the University of Cambridge and an MBA from the London Business School.
Financial terms:
Latest news:
Is general: Yes
